OR-CXL-CONSORTIUM
10.11.2020 15:02:13 CET | Business Wire | Press release
The CXL™ Consortium, an industry standards body dedicated to advancing Compute Express Link™ (CXL) technology, today announced the release of the CXL 2.0 specification. CXL is an open industry-standard interconnect offering coherency and memory semantics using high-bandwidth, low-latency connectivity between host processor and devices such as accelerators, memory buffers, and smart I/O devices. The CXL 2.0 specification adds support for switching for fan-out to connect to more devices; memory pooling for increased memory utilization efficiency and providing memory capacity on demand; and support for persistent memory – all while preserving industry investments by supporting full backwards compatibility with CXL 1.1 and 1.0.
“Datacenter architectures continue to evolve rapidly to support the growing demands of emerging workloads for Artificial Intelligence and Machine Learning, with CXL technology keeping pace to meet the performance and latency demands,” said Barry McAuliffe, president, CXL Consortium. “Designed with breakthrough performance and easy adoption as guiding principles, the CXL 2.0 specification is a significant achievement from our dedicated technical work group members.”
Key Highlights of the CXL 2.0 Specification:
- Adds support for switching to enable device fan-out, memory scaling, expansion and the migration of resources.
- Includes memory pooling support to maximize memory utilization, limiting or eliminating the need to overprovision memory.
- Introduces standardized fabric manager specification for inventory and resource allocation to enable easier adoption and management of CXL-based switch and fabric solutions.
- Provides standardized management of the persistent memory interface and enables simultaneous operation alongside DDR, freeing up DDR for other uses.
- Introduces managed hot-plug support to take a CXL device online or offline from the system.
- Adds link-level Integrity and Data Encryption (CXL IDE) to provide confidentiality, integrity and replay protection for data transiting the CXL link.
- Supports a wide variety of industry interconnect form factors and standardized management interfaces to ease implementation.
- Includes Compliance and Interoperability specifications and in-system testing to enable a robust and interoperable multi-vendor ecosystem.
“The CXL Consortium has moved with breathtaking speed to deliver its second generation CXL 2.0 spec, even before products incorporating the first generation CXL 1.0 and 1.1 specs have reached the market,” observed Nathan Brookwood, Research Fellow at Insight 64. “The new 2.0 features, including switching, memory pooling and persistent memory support pave the way for fully disaggregated systems in which pools of accelerators, DRAM and persistent memory storage can be dynamically connected to any one of 16 host servers to meet application demands. These features will enable system designers to invent entirely new types of systems that architects could only dream about just a few years ago.”
The CXL 2.0 specification is available for public download at https://www.computeexpresslink.org/download-the-specification .
Additional Resources:
- White Paper: Introducing the CXL 2.0 Specification
- CXL Consortium Member Company Statements of Support
About the CXL™ Consortium
The CXL Consortium is an industry standards body dedicated to advancing Compute Express Link™ (CXL) technology. CXL is a high-speed interconnect offering coherency and memory semantics using high-bandwidth, low-latency connectivity between the host processor and devices such as accelerators, memory buffers, and smart I/O devices. For more information or to join, visit www.computeexpresslink.org .
Compute Express Link and CXL are trademarks of the CXL Consortium. All other trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201110005037/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alsym Energy Announces Na-Series Battery Success Developed With Physics-Informed AI Platform27.4.2026 21:25:00 CEST | Press release
Alsym’s proprietary physics-informed AI platform powered the development of its Na-Series batteries—a non-flammable, high performance and low cost energy solution positioned to serve critical energy storage markets including data centers, utilities, telecommunications, commercial real estate, industrial and defense, among others. Alsym Energy, a pioneer in non-flammable, high-performance sodium-ion batteries, today announced details of the proprietary physics-informed AI platform used to develop the company’s recently launched Na-Series sodium-ion batteries. By integrating fundamental physics models with AI, autonomous testing and proprietary molecular diagnostics in a closed-loop system, Alsym is accelerating the design of safer, inexpensive, commercialized batteries through all phases of the development cycle. As global demand for electricity surges, the limitations of lithium-ion batteries have become increasingly apparent, particularly around safety and supply chain constraints. Li
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
